Paris based Cellectis therapeutics announced last January that a team of scientists had successfully used its Meganucleases to block an HSV-1 herpes infection. This is the first proof that meganucleses can be used to prevent viral infection.
The implication of this new technique for preventing the spread of virus has the potential to revolutionize research into a herpes vaccine.
Dr Marc Labetoulle of CNRS (French National Center for Medical Research) a participating partner, said: “The results published in Molecular Therapy are very exciting since they open new fields of research for fighting HSV recurrent infections.”
Celletics seems to be faced with some patent disputes regarding Meganucleases with another company, Precison though. I hope this will not hinder their progress in this very interesting and promising treatment research.
